PTA is an effective therapy to prepare the vessel for treatment with DEB • IN.PACT SFA Trial had a 96.4% predilatation rate in the DEB arm Stents can be useful for the treatment of residual stenosis, flow-limiting dissection and recoil. • The potential for chronic vessel injury and fracture is a clear obstacle for metallic stents. By limiting the use of metallic stents, future options are preserved for any later re-intervention. • IN.PACT SFA Trial had a low 7.3% provisional stent rate in the DEB arm. Drug-eluting balloon therapy provide options to keep the AV access site open.
Treat with Ease - New 40 cm Catheter Short 40 & 80 cm catheters allow for shorter wires and simplified handling. • IN.PACT Admiral has the highest reported primary patency rate, 89.8%, of available SFA technologies, while minimizing the use of durable implants. • IN.PACT Admiral has the lowest reported clinically driven TLR (CD-TLR) rate, 2.4%, of available SFA technologies. • Re-intervention is a significant component of added cost to lower extremity PAD management. A therapy with proven lower re-intervention rates, meaning a reduced likelihood of an expensive repeat procedure, should lower overall costs for the healthcare system.
